Human Mab RV6-26 was sequenced from RV-specific B cells isolated from the blood of healthy adult donors or RV-infected infants or adults5,6.
≥ 5.0 mg/ml
< 1.0 EU/mg as determined by the LAL method
≥95% monomer by analytical SEC
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Standard Overnight on Blue Ice.
Other Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
RV6-26 activity is directed against a quaternary epitope on VP6.
This human monoclonal antibody RV6-26 binds at the viral RNA release pore in the DLP5 and is able to neutralize RV by inhibiting transcription7. Structural data suggest steric hindrance inhibits the transcriptional pore7.
Rotaviruses (RV) are double-stranded, non-enveloped, icosahedral RNA viruses in the Reoviridae family1 that cause severe dehydrating diarrhea in infants and children2. RV particles are composed of concentric viral protein (VP) layers3. The triple-layered particle has an inner capsid layer (VP2), an intermediate capsid layer (VP6), and an outer capsid layer (VP7, VP4). The transcriptionally active double-layered particle (DLP) consists of VP2 and VP6. VP6 is the most antigenic RV protein in humans4. The antibody VH1–46 gene segment is the site of primary interaction with VP65.
References & Citations
1. Aiyegbo MS, Eli IM, Spiller BW, et al. J Virol. 88(1):469-76. 2014.
2. Bern C, Martines J, de Zoysa I, et al. Bull World Health Organ. 70: 705-714. 1992.
3. Pesavento, JB, Crawford SE, Estes MK, et al. Curr Top Microbiol Immunol. 309: 189-219. 2006.
4. McKinney BA, Kallewaard NL, Crowe JE, et al. Immunome Res 3:8. 2007.
5. Kallewaard NL, McKinney BA, Gu Y, et al. J Immunol. 180(6):3980-9. 2008.
6. Weitkamp JH, Kallewaard N, Kusuhara K, et al. J Immunol Methods. 275:223–237. 2003.
7. Aiyegbo MS, Sapparapu G, Spiller BW, et al. PLoS ONE. 8(5): e61101. 2013.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.